High Cytoplasm HABP1 Expression As a Predictor of Poor Survival and Late Tumor Stage in Pancreatic Ductal Adenocarcinoma Patients.

Zhi-Bo Xie,Lie Yao,Chen Jin,Yi-Fan Zhang,De-Liang Fu
DOI: https://doi.org/10.1016/j.ejso.2018.09.020
IF: 4.037
2019-01-01
European Journal of Surgical Oncology
Abstract:Background: Hyaluronan-binding protein 1 (HABP1) overexpression has been confirmed in different malignancies and found to be strongly associated with tumor development and progression. The aim of the present study was to explore the impact of HABP1 in pancreatic ductal adenocarcinoma (PDAC) patients. Method: HABP1 expression was evaluated in 89 PDAC specimens. Results: The expression of HABP1 was significantly higher in tumor tissues than that in adjacent normal tissues. High nucleus HABP1 expression and high cytoplasm HABP1 expression were both detected in PDAC tissues. Overall survival analysis by optical density showed that the mean survival was similar between patients with low and high optical density values of HABP1 expression (P = 0.312). The similar result was also found between patients with low-moderate or high nucleus HABP1 expression (P = 0.275). However, the mean survival was significantly poorer in patients with cytoplasm HABP1 overexpression (P < 0.001). High cytoplasm HABP1 expression was strongly correlated with late tumor stages, arterial involvement, lymph node metastasis and carbohydrate antigen 19-9 levels. Conclusion: High cytoplasm HABP1 expression may prove to be a predictor of poor survival and late tumor stage in PDAC patients. HABP1 could serve as a promising biomarker to identify subsets of PDAC patients with high malignant clinical behavior. (C) 2018 Elsevier Ltd, BASO similar to The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
What problem does this paper attempt to address?